Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
WHO, 2005. Malaria Control Today. Current WHO Recommendations. Geneva: World Health Organization, Roll Back Malaria Department, 1–75.
-
2
Breman JG, 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64 :1–11.
-
3
Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 :97–106.
-
4
Webster D, Hill AVS, 2003. Progress with new malaria vaccines. Bull World Health Organ 81 :902–910.
-
5
Tsuboi T, Tachibana M, Kaneko TO, Torii M, 2003. Transmission-blocking vaccine of P. vivax malaria. Parasitol Int 52 :1–11.
-
6
Mendis KN, Menesinghe Y, da Silva YN, Keragalla I, Carter R, 1987. Malaria transmission blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect Immun 55 :369–372.
-
7
Hoffman SL, Franke ED, Hollingdale MR, Druilhe P, 1996. Perspectives on malaria vaccine development. Hoffman SL, ed. Malaria Vaccine Development. A Multi-Immune Response Approach. Washington, DC: American Society of Microbiology Press, 1–14.
-
8
Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS, 1987. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 139 :2020–2025.
-
9
Gamage-Mendis AC, Rajakaruna J, Carter R, Mendis KN, 1992. Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka. Parasite Immunol 14 :385–396.
-
10
Ramsey JM, Salinas E, Rodriguez MH, 1996. Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am J Trop Med Hyg 54 :458–463.
-
11
Mendez F, Carrasquilla G, Muñoz A, 2000. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg 94 :367–371.
-
12
Gonzalez JM, Olano V, Vergara J, Arevalo-Herrera M, Carrasquilla G, Herrera S, Lopez JA, 1997. Unstable, low-level transmission of malaria on the Colombian Pacific coast. Ann Trop Med Parasitol 91 :349–358.
-
13
Shute GT, 1988. The microscopic diagnosis of malaria. Wernsdorfer H, McGregor IA, eds. Principles and Practice of Malariology. London: Longman Group UK Limited, 781–814.
-
14
Lensen A, von Druten J, Bolmer M, von Gemert J, Eling W, Sauerwein RW, 1996. Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic area. Trans R Soc Trop Med Hyg 90 :20–22.
-
15
Mendis C, Gamage-Mendis AC, de Zoysa AP, Abhayawardena TA, Carter R, Herath PR, Mendis KN, 1990. Characteristics of malaria transmission in Kataragama, Sri Lanka: a focus for immunoepidemiological studies. Am J Trop Med Hyg 42 :298–308.
-
16
Peiris JS, Premawansa S, Ranawaka MB, Udagama PV, Munasinghe YD, Nanayakkara MV, Gamage CP, Carter R, David PH, Mendis KN, 1988. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. Am J Trop Med Hyg 39 :26–32.
-
17
Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, 2005. Phase I vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 :3131–3138.
-
18
Karunaweera ND, Wijesekera SK, Wanasekera D, Mendis KN, Carter R, 2003. The paroxysm of Plasmodium vivax malaria. Trends Parasitol 19 :188–193.
-
19
Collins EW, Jeffery GM, Roberts JM, 2004. A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax.Am J Trop Med Hyg 70 :638–641.
-
20
Wijesekera SK, Carter R, Rathnayaka L, Mendis KN, 1996. A malaria parasite toxin associated with Plasmodium vivax paroxysms. Clin Exp Immunol 104 :221–227.
-
21
Naotunne T, Karunaweera ND, Mendis KN, Carter R, 1993. Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white cells. Immunology 78 :555–562.
-
22
Naotunne T, Karunaweera ND, del Giudice G, Kularatne MU, Grau GE, Carter R, Mendis K, 1991. Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med 173 :523–529.
-
23
Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC, 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68 :6618–6623.
-
24
Healer DJ, McGuinness P, Hopcroft SH, Carter R, Riley E, 1997. Complement-mediated lysis of Plasmodium falciparum gametes by malaria- immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect Immun 65 :3017–3023.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 65 | 65 | 6 |
| Full Text Views | 322 | 48 | 0 |
| PDF Downloads | 103 | 17 | 0 |
PLASMODIUM VIVAX: TRANSMISSION-BLOCKING IMMUNITY IN A MALARIA-ENDEMIC AREA OF COLOMBIA
MYRIAM ARÉVALO-HERRERA
MYRIAM ARÉVALO-HERRERA
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by MYRIAM ARÉVALO-HERRERA in
Current site
Google Scholar
PubMed
Search for other papers by MYRIAM ARÉVALO-HERRERA in
Current site
Google Scholar
PubMed
YEZID SOLARTE
YEZID SOLARTE
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by YEZID SOLARTE in
Current site
Google Scholar
PubMed
Search for other papers by YEZID SOLARTE in
Current site
Google Scholar
PubMed
FELIPE ZAMORA
FELIPE ZAMORA
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by FELIPE ZAMORA in
Current site
Google Scholar
PubMed
Search for other papers by FELIPE ZAMORA in
Current site
Google Scholar
PubMed
FABIÁN MENDEZ
FABIÁN MENDEZ
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by FABIÁN MENDEZ in
Current site
Google Scholar
PubMed
Search for other papers by FABIÁN MENDEZ in
Current site
Google Scholar
PubMed
MARIA FERNANDA YASNOT
MARIA FERNANDA YASNOT
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by MARIA FERNANDA YASNOT in
Current site
Google Scholar
PubMed
Search for other papers by MARIA FERNANDA YASNOT in
Current site
Google Scholar
PubMed
LEONARDO ROCHA
LEONARDO ROCHA
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by LEONARDO ROCHA in
Current site
Google Scholar
PubMed
Search for other papers by LEONARDO ROCHA in
Current site
Google Scholar
PubMed
CAROLE LONG
CAROLE LONG
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by CAROLE LONG in
Current site
Google Scholar
PubMed
Search for other papers by CAROLE LONG in
Current site
Google Scholar
PubMed
LOUIS H. MILLER
LOUIS H. MILLER
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by LOUIS H. MILLER in
Current site
Google Scholar
PubMed
Search for other papers by LOUIS H. MILLER in
Current site
Google Scholar
PubMed
SÓCRATES HERRERA
SÓCRATES HERRERA
Instituto de Inmunología del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia, School of Public Health, Universidad del Valle, Cali, Colombia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Search for other papers by SÓCRATES HERRERA in
Current site
Google Scholar
PubMed
Search for other papers by SÓCRATES HERRERA in
Current site
Google Scholar
PubMed
Plasmodium vivax transmission-blocking activity was assessed in sera from acutely infected patients from a malaria-endemic area in Colombia. We measured reduction in the number of oocysts that developed in the midguts of Anopheles albimanus mosquitoes artificially fed with blood from these patients. Of 88 mosquito batches that developed infections when parasites were mixed with normal AB human serum, one-third (36.4%) showed full transmission-blocking activity (≥ 90% inhibition) when mixed with autologous sera, 29.6% showed partial activity (50–89%), 17.0% did not block transmission (0–50%), and 17% did not enhance transmission. Transmission-blocking activity correlated with antibody titer by an immunofluorescent antibody test and decreased with the serial dilution of the sera. This activity disappeared at a 1:4 dilution in most sera tested. Afro-Colombian individuals showed lower activity than other ethnic groups and febrile patients produced stronger inhibition than those without fever.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
WHO, 2005. Malaria Control Today. Current WHO Recommendations. Geneva: World Health Organization, Roll Back Malaria Department, 1–75.
-
2
Breman JG, 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64 :1–11.
-
3
Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 :97–106.
-
4
Webster D, Hill AVS, 2003. Progress with new malaria vaccines. Bull World Health Organ 81 :902–910.
-
5
Tsuboi T, Tachibana M, Kaneko TO, Torii M, 2003. Transmission-blocking vaccine of P. vivax malaria. Parasitol Int 52 :1–11.
-
6
Mendis KN, Menesinghe Y, da Silva YN, Keragalla I, Carter R, 1987. Malaria transmission blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect Immun 55 :369–372.
-
7
Hoffman SL, Franke ED, Hollingdale MR, Druilhe P, 1996. Perspectives on malaria vaccine development. Hoffman SL, ed. Malaria Vaccine Development. A Multi-Immune Response Approach. Washington, DC: American Society of Microbiology Press, 1–14.
-
8
Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS, 1987. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 139 :2020–2025.
-
9
Gamage-Mendis AC, Rajakaruna J, Carter R, Mendis KN, 1992. Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka. Parasite Immunol 14 :385–396.
-
10
Ramsey JM, Salinas E, Rodriguez MH, 1996. Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am J Trop Med Hyg 54 :458–463.
-
11
Mendez F, Carrasquilla G, Muñoz A, 2000. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg 94 :367–371.
-
12
Gonzalez JM, Olano V, Vergara J, Arevalo-Herrera M, Carrasquilla G, Herrera S, Lopez JA, 1997. Unstable, low-level transmission of malaria on the Colombian Pacific coast. Ann Trop Med Parasitol 91 :349–358.
-
13
Shute GT, 1988. The microscopic diagnosis of malaria. Wernsdorfer H, McGregor IA, eds. Principles and Practice of Malariology. London: Longman Group UK Limited, 781–814.
-
14
Lensen A, von Druten J, Bolmer M, von Gemert J, Eling W, Sauerwein RW, 1996. Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic area. Trans R Soc Trop Med Hyg 90 :20–22.
-
15
Mendis C, Gamage-Mendis AC, de Zoysa AP, Abhayawardena TA, Carter R, Herath PR, Mendis KN, 1990. Characteristics of malaria transmission in Kataragama, Sri Lanka: a focus for immunoepidemiological studies. Am J Trop Med Hyg 42 :298–308.
-
16
Peiris JS, Premawansa S, Ranawaka MB, Udagama PV, Munasinghe YD, Nanayakkara MV, Gamage CP, Carter R, David PH, Mendis KN, 1988. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. Am J Trop Med Hyg 39 :26–32.
-
17
Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, 2005. Phase I vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 :3131–3138.
-
18
Karunaweera ND, Wijesekera SK, Wanasekera D, Mendis KN, Carter R, 2003. The paroxysm of Plasmodium vivax malaria. Trends Parasitol 19 :188–193.
-
19
Collins EW, Jeffery GM, Roberts JM, 2004. A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax.Am J Trop Med Hyg 70 :638–641.
-
20
Wijesekera SK, Carter R, Rathnayaka L, Mendis KN, 1996. A malaria parasite toxin associated with Plasmodium vivax paroxysms. Clin Exp Immunol 104 :221–227.
-
21
Naotunne T, Karunaweera ND, Mendis KN, Carter R, 1993. Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white cells. Immunology 78 :555–562.
-
22
Naotunne T, Karunaweera ND, del Giudice G, Kularatne MU, Grau GE, Carter R, Mendis K, 1991. Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med 173 :523–529.
-
23
Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC, 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68 :6618–6623.
-
24
Healer DJ, McGuinness P, Hopcroft SH, Carter R, Riley E, 1997. Complement-mediated lysis of Plasmodium falciparum gametes by malaria- immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect Immun 65 :3017–3023.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 65 | 65 | 6 |
| Full Text Views | 322 | 48 | 0 |
| PDF Downloads | 103 | 17 | 0 |